Visible response rate in relapsed or refractory patients

ABRAXANE increased recTLRR in patients who failed combination chemotherapy or relapsed within 6 months of adjuvant chemotherapya

Tumor response in relapsed and refractory patients
aPrior therapy included an anthracycline unless clinically contraindicated.
ITT=intent-to-treat.

59% of ITT patients had failed combination chemotherapy or relapsed within 6 months of adjuvant chemotherapya

How did the study define recTLRR?”
  • recTLRR was the prospectively defined, protocol-specific end point, based on independent radiologic assessment of tumor responses reconciled with investigator responses (which also included clinical information) for the first 6 cycles of therapy. The recTLRR was lower than the investigator-reported response rates, which are based on all cycles of therapy
Trial design

Visible response rate in relapsed or refractory patients

ABRAXANE increased recTLRR in patients who failed combination chemotherapy or relapsed within 6 months of adjuvant chemotherapya

Tumor response in relapsed and refractory patients
aPrior therapy included an anthracycline unless clinically contraindicated.
ITT=intent-to-treat.

59% of ITT patients had failed combination chemotherapy or relapsed within 6 months of adjuvant chemotherapya

  • recTLRR was the prospectively defined, protocol-specific end point, based on independent radiologic assessment of tumor responses reconciled with investigator responses (which also included clinical information) for the first 6 cycles of therapy. The recTLRR was lower than the investigator-reported response rates, which are based on all cycles of therapy
Trial Design

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.